PDF(Pubmed)
Abstract：
BACKGROUND: Male breast cancer (MBC) is a rare disease. Although several large-scale studies have investigated MBC patients in other countries, the features of MBC patients in China have not been fully explored. This study aims to explore the features of Chinese MBC patients comprehensively.
METHODS: We retrospectively collected data of MBC patients from 36 centers in China. Overall survival (OS) was evaluated by the Kaplan-Meier method, log-rank test, and Cox regression analyses. Multivariate Cox analyses were used to identify independent prognostic factors of the patients.
RESULTS: In total, 1119 patients were included. The mean age at diagnosis was 60.9 years, and a significant extension over time was observed (P < 0.001). The majority of the patients (89.1 %) received mastectomy. Sentinel lymph node biopsy was performed in 7.8 % of the patients diagnosed in 2009 or earlier, and this percentage increased significantly to 38.8 % in 2020 or later (P < 0.001). The five-year OS rate for the population was 85.5 % [95 % confidence interval (CI), 82.8 %-88.4 %]. Multivariate Cox analysis identified taxane-based [T-based, hazard ratio (HR) = 0.32, 95 % CI, 0.13 to 0.78, P = 0.012] and anthracycline plus taxane-based (A + T-based, HR = 0.47, 95 % CI, 0.23 to 0.96, P = 0.037) regimens as independent protective factors for OS. However, the anthracycline-based regimen showed no significance in outcome (P = 0.175).
CONCLUSIONS: As the most extensive MBC study in China, we described the characteristics, treatment and prognosis of Chinese MBC population comprehensively. T-based and A + T-based regimens were protective factors for OS in these patients. More research is required for this population.
METHODS: We retrospectively collected data of MBC patients from 36 centers in China. Overall survival (OS) was evaluated by the Kaplan-Meier method, log-rank test, and Cox regression analyses. Multivariate Cox analyses were used to identify independent prognostic factors of the patients.
RESULTS: In total, 1119 patients were included. The mean age at diagnosis was 60.9 years, and a significant extension over time was observed (P < 0.001). The majority of the patients (89.1 %) received mastectomy. Sentinel lymph node biopsy was performed in 7.8 % of the patients diagnosed in 2009 or earlier, and this percentage increased significantly to 38.8 % in 2020 or later (P < 0.001). The five-year OS rate for the population was 85.5 % [95 % confidence interval (CI), 82.8 %-88.4 %]. Multivariate Cox analysis identified taxane-based [T-based, hazard ratio (HR) = 0.32, 95 % CI, 0.13 to 0.78, P = 0.012] and anthracycline plus taxane-based (A + T-based, HR = 0.47, 95 % CI, 0.23 to 0.96, P = 0.037) regimens as independent protective factors for OS. However, the anthracycline-based regimen showed no significance in outcome (P = 0.175).
CONCLUSIONS: As the most extensive MBC study in China, we described the characteristics, treatment and prognosis of Chinese MBC population comprehensively. T-based and A + T-based regimens were protective factors for OS in these patients. More research is required for this population.
摘要：
背景：男性乳腺癌（MBC）是一种罕见的疾病。尽管一些大规模研究调查了其他国家的MBC患者，中国MBC患者的特征尚未得到充分探索。本研究旨在全面探讨中国MBC患者的特点。
方法：我们回顾性收集了来自中国36个中心的MBC患者的数据。通过Kaplan-Meier方法评估总生存期(OS)，对数秩检验，和Cox回归分析。多因素Cox分析用于确定患者的独立预后因素。
结果：总计，纳入1119例患者。诊断时的平均年龄为60.9岁,并且随着时间的推移观察到显著的延长(P<0.001)。大多数患者（89.1％）接受了乳房切除术。在2009年或更早诊断的患者中，有7.8％进行了前哨淋巴结活检，这一比例在2020年及以后大幅上升至38.8%(P<0.001)。人口的五年OS率为85.5%[95%置信区间(CI)，82.8%-88.4%]。多变量Cox分析确定了基于紫杉烷的[基于T，危险比（HR）=0.32，95%CI，0.13至0.78，P=0.012]和蒽环类抗生素加紫杉烷（基于A+T，HR=0.47,95%CI,0.23~0.96,P=0.037)方案作为OS的独立保护因素。然而,以蒽环类抗生素为基础的治疗方案在结局方面无显著性意义(P=0.175).
结论：作为中国最广泛的MBC研究，我们描述了特点，中国MBC人群的综合治疗和预后。在这些患者中，基于T和基于A+T的方案是OS的保护因素。对这个群体需要更多的研究。
方法：我们回顾性收集了来自中国36个中心的MBC患者的数据。通过Kaplan-Meier方法评估总生存期(OS)，对数秩检验，和Cox回归分析。多因素Cox分析用于确定患者的独立预后因素。
结果：总计，纳入1119例患者。诊断时的平均年龄为60.9岁,并且随着时间的推移观察到显著的延长(P<0.001)。大多数患者（89.1％）接受了乳房切除术。在2009年或更早诊断的患者中，有7.8％进行了前哨淋巴结活检，这一比例在2020年及以后大幅上升至38.8%(P<0.001)。人口的五年OS率为85.5%[95%置信区间(CI)，82.8%-88.4%]。多变量Cox分析确定了基于紫杉烷的[基于T，危险比（HR）=0.32，95%CI，0.13至0.78，P=0.012]和蒽环类抗生素加紫杉烷（基于A+T，HR=0.47,95%CI,0.23~0.96,P=0.037)方案作为OS的独立保护因素。然而,以蒽环类抗生素为基础的治疗方案在结局方面无显著性意义(P=0.175).
结论：作为中国最广泛的MBC研究，我们描述了特点，中国MBC人群的综合治疗和预后。在这些患者中，基于T和基于A+T的方案是OS的保护因素。对这个群体需要更多的研究。
